Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][8]. Core Insights - The company is accelerating its overseas clinical trials for the drug SSGJ-707, with a significant upfront payment of 2.89 billion RMB from Pfizer, contributing to an expected total revenue of 9.63 billion RMB from this authorization in 2025 [6][7]. - Pfizer has initiated the first patient enrollment for the Phase III clinical trial of SSGJ-707 targeting mCRC, marking a significant milestone as the first MRCT Phase III trial conducted by a multinational corporation in the PD-1/VEGF field [7]. - The company has a rich pipeline with multiple catalysts expected in 2026, including the anticipated approval of three new molecular entities and the ongoing progress of global Phase III clinical trials for SSGJ-707 [7]. Financial Projections - Revenue projections for the company are estimated at 19.216 billion RMB for 2025, with a growth rate of 111%, followed by 11.085 billion RMB in 2026, reflecting a decline of 42%, and a recovery to 12.906 billion RMB in 2027, with a growth rate of 16% [9][10]. - The net profit attributable to the parent company is projected to be 10.967 billion RMB in 2025, with a significant increase of 425%, followed by a decrease to 2.443 billion RMB in 2026, and an increase to 3.411 billion RMB in 2027 [9][10]. - The report anticipates a price-to-earnings (P/E) ratio of 4.8x for 2025, 21.6x for 2026, and 15.4x for 2027, indicating a potential for valuation adjustments as new products are launched [9][10].
三生制药（01530）：动态研究：707 全球三期临床 FPI，海外临床加速推进